Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Number of cured patients
研究概览
简要总结
Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells
详细描述
During the implementation of the project, it is planned to develop a method for the treatment of severe covid-19 associated interstitial pneumonia using allogeneic mesenchymal stem cells. The positive outlook for the effectiveness of MSCs is due to the following:
- knowledge of the leading role of immunopathogenetic mechanisms in the development of acute interstitial lung diseases and the pronounced immunomodulating properties of MSCs;
- high tropism of MSCs to lung tissue when administered intravenously;
- the ability of MSCs to stimulate tissue regeneration and the effective use of MSCs in the treatment of acute damage to the myocardium and kidneys, which will contribute to the treatment of multiple organ failure;
- positive results of preclinical studies of the method of treatment of viral pneumonia in animals, and the first clinical studies in patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PCR-confirmed Covid-19 pneumonia
- •respiratory failure
排除标准
- •diagnosed cancer
研究组 & 干预措施
mesenchymal stem cells
Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells
干预措施: Standard treatment according to the Clinical protocols (Other)
control
Patients with Covid-19 associated pneumonia receiving standard treatment
干预措施: Standard treatment according to the Clinical protocols (Other)
mesenchymal stem cells
Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells
干预措施: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells (Biological)
结局指标
主要结局
Number of cured patients
时间窗: 3 weeks
Number of patients cured, assessed by PCR in addition to chest CT scan
次要结局
- Number of patients with treatment-related adverse events(3 weeks)